This inventor holds 1 USPTO granted patent. Top assignee: The University of Edinburgh. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Charalampos Ioannidis: Innovator in Cyclophilin Modulation
Introduction
Charalampos Ioannidis is a notable inventor based in Edinburgh, GB. He has made significant contributions to the field of pharmaceutical sciences, particularly in the modulation of cyclophilins. His work focuses on developing compounds that can serve as inhibitors of cyclophilins and modulators of cyclophilin-like proteins.
Latest Patents
Ioannidis holds a patent for "Compounds for the modulation of cyclophilins function." This invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, which are useful as inhibitors of cyclophilins. The patent also discusses the applications of these compounds in treating various disorders. The detailed formula includes various groups and substituents that enhance the efficacy of the compounds.
Career Highlights
Charalampos Ioannidis is affiliated with the University of Edinburgh, where he conducts his research and development activities. His work has led to advancements in understanding the role of cyclophilins in various biological processes. He has been recognized for his innovative approach to drug development.
Collaborations
Some of his notable coworkers include Malcolm Walkinshaw and Alessio De Simone. Their collaborative efforts have contributed to the success of his research projects and patent applications.
Conclusion
Charalampos Ioannidis is a prominent figure in the field of pharmaceutical innovation, with a focus on cyclophilin modulation. His contributions are paving the way for new therapeutic options in treating various disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
